Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
GLENMARK
Mr. Glenn Mario Saldanha · Mumbai, India
₹2,261.70
▲+3.53%Glenmark is trading near its 52-week high after a positive session, reflecting optimism around its specialty and generic drug portfolio despite premium valuation.
Exchange
NSI
Currency
INR
Day range
₹2,186.20 – ₹2,267.70
52-week range
₹1,792.60 – ₹2,474.00
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis75% confidence
Current valuation appears stretched with a P/E of 46.85, trading in the upper third of its 52-week range, suggesting limited upside near-term unless earnings growth accelerates.
8.6% below the 1-year high · trend up
Hedge-fund memo
Today
The stock rose 3.53% on positive momentum, trading near the day's high within its recent range.
This week
The stock appears to be consolidating near recent highs after a strong run-up.
This month
The stock has shown strong performance, approaching its 52-week high, indicating positive sentiment.
Bull thesis
Bear thesis
Hidden risks
News & sentiment
Neutral
23 headlines · 21 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 2 of 3 recent quarters (EPS actual vs. consensus).
20.961 vs 18.3
14.54% surprise
19.2097 vs 19.2
0.05% surprise
7.2861 vs 12.9
-43.52% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| GLENMARK | 638.25B | 46.85 | 14.07% | 16.30% | 14.30% |
| LUPIN | 1.12T | 21.02 | 26.91% | 24.22% | 31.90% |
| AUROPHARMA | 915.25B | 26.40 | 9.93% |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Generic drug pricing pressure in key markets
Mitigation: Continued focus on specialty drugs and higher margin products
Pipeline execution risks for new drug candidates
Mitigation: Diversified pipeline across multiple therapeutic areas
Business intelligence
Competitive moat
Strong R&D capabilities in specialty pharmaceuticals and established manufacturing footprint across multiple markets.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
New drug approvals in specialty segments
Earnings report with guidance
Thesis builder
Bull case
Strong growth in specialty pharmaceuticals and expanding international presence drive sustained revenue growth and margin expansion.
Base case
Maintains steady performance in generic markets while gradually building specialty portfolio, delivering mid-teens revenue growth.
Bear case
Pricing pressures in generic markets and delays in specialty drug development could pressure growth and margins.
Time horizon
Medium to long term (12-24 months)
Est. CAGR
12-15%
Entry (qual.)
Consider on pullbacks toward 2000-2100 INR levels for better risk-reward
Exit (qual.)
Exit if the stock consistently fails to break above 2500 INR or fundamentals deteriorate
Overall conviction 75%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how GLENMARK fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain GLENMARK for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
The stock is attractive for long-term investors but current valuation offers limited margin of safety.
ET Pharma·1d ago·enters large US hospital injectables market
eHealth Magazine·1d ago·expands US hospital injectables portfolio
Indian Pharma Post·1d ago·enters large US injectables market
Sahi·1d ago·launches in $1.6B US market
Business Upturn·1d ago·minor stock price movement
scanx.trade·1d ago·launches in $1.6B US market
PR Newswire·1d ago·enters US hospital injectables market
Whalesbook·1d ago·enters $120B US market
Whalesbook·1d ago·enters $130B US market
Goodreturns·2d ago·launches semaglutide in India
The Press·3d ago·unrelated rugby stadium news
MarketsMojo·3d ago·mixed derivatives activity noted
giant.fm·3d ago·government settlement payment
ODT·3d ago·unrelated rugby title
St. George News·3d ago·$29.6M price inflation settlement
TradingView·4d ago·financial metric analysis
TradingView·4d ago·financial metric analysis
Machine Maker·5d ago·FDA approves pediatric indication
Marksmen Daily·6d ago·executive interview unrelated
equitypandit.com·6d ago·weekly outlook commentary
Canterbury Rugby·6d ago·unrelated rugby event
Word & Brown General Agency·6d ago·$29M drug pricing settlement
EIN News·7d ago·$29.6M price inflation settlement
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
| 14.94% |
| 5.60% |
| BIOCON | 701.96B | 153.42 | 1.15% | 15.56% | 2.30% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹2,186.20
Resistance (day/52w high)
₹2,267.70
Volume
5,93,712
Trend
up
RSI (14)
49
MACD
bearish
MA cross
golden
50-day MA
₹2,227.05
200-day MA
₹2,103.35
vs 200-DMA
7.5%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.